Werewolf Therapeutics (HOWL) Competitors

$0.44 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.44 0.00 (-0.81%)

As of 05/22/2026 07:56 PM Eastern

HOWL vs. CUE, EXOZ, FRMM, BHST, and BTMD

Should you buy Werewolf Therapeutics stock or one of its competitors? MarketBeat compares Werewolf Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Werewolf Therapeutics include Cue Biopharma (CUE), eXoZymes (EXOZ), Forum Markets (FRMM), BioHarvest Sciences (BHST), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Werewolf Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 745.36%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Werewolf Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 1.8% of Cue Biopharma shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cue Biopharma has higher revenue and earnings than Werewolf Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.17	-$26.60M	-$5.58	N/A
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A

Cue Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 2 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of -0.12 beat Werewolf Therapeutics' score of -0.29 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Werewolf Therapeutics beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to eXoZymes?

Werewolf Therapeutics (NASDAQ:HOWL) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

In the previous week, Werewolf Therapeutics had 4 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.29 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
eXoZymes	Neutral

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 745.36%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Werewolf Therapeutics' return on equity of -208.23% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
eXoZymes	N/A	-220.63%	-141.26%

eXoZymes has lower revenue, but higher earnings than Werewolf Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A
eXoZymes	$70K	1,201.74	-$9.16M	-$1.14	N/A

Summary

Werewolf Therapeutics beats eXoZymes on 9 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Forum Markets presently has a consensus price target of $10.00, suggesting a potential upside of 120.26%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 745.36%. Given Werewolf Therapeutics' higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Werewolf Therapeutics had 3 more articles in the media than Forum Markets. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 1 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.29 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 15.1% of Forum Markets shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has lower revenue, but higher earnings than Forum Markets. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	10.08	-$450.52M	-$36.07	N/A
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A

Forum Markets has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Werewolf Therapeutics' return on equity of -208.23% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Summary

Werewolf Therapeutics beats Forum Markets on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 159.07%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 745.36%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioHarvest Sciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

BioHarvest Sciences has higher revenue and earnings than Werewolf Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A

Werewolf Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

In the previous week, BioHarvest Sciences had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 7 mentions for BioHarvest Sciences and 4 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of -0.29 beat BioHarvest Sciences' score of -0.30 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioHarvest Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Werewolf Therapeutics beats BioHarvest Sciences on 9 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to biote?

biote (NASDAQ:BTMD) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

biote has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.52
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A

21.7% of biote shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

biote has a net margin of 8.29% compared to Werewolf Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

biote presently has a consensus target price of $2.75, indicating a potential upside of 38.19%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 745.36%. Given Werewolf Therapeutics' higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

biote has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

In the previous week, Werewolf Therapeutics had 4 more articles in the media than biote. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 0 mentions for biote. biote's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.29 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Neutral
Werewolf Therapeutics	Neutral

Summary

biote beats Werewolf Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.56M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.36	18.74	21.00	25.66
Price / Sales	11.47	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.77	7.09	10.41	7.14
Net Income	-$60.82M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.55%	6.38%	6.40%	4.11%
1 Month Performance	-45.44%	2.43%	3.54%	2.52%
1 Year Performance	-61.43%	62.98%	34.14%	35.04%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	3.05 of 5 stars	$0.44 flat	$3.75 +745.4%	-61.4%	$21.56M	$1.88M	N/A	40	Gap Down
CUE Cue Biopharma	0.6683 of 5 stars	$20.30 -5.0%	N/A	-96.4%	$82.22M	$27.47M	N/A	60	Gap Down
EXOZ eXoZymes	0.1264 of 5 stars	$9.60 +0.5%	N/A	-33.4%	$81.41M	$70K	N/A	29	Gap Up
FRMM Forum Markets	2.1584 of 5 stars	$3.89 +4.2%	$10.00 +157.3%	N/A	$78.88M	$6.55M	N/A	7	Positive News Gap Up
BHST BioHarvest Sciences	2.4533 of 5 stars	$3.95 -0.4%	$10.00 +153.5%	-38.6%	$77.39M	$35.16M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. CUE, EXOZ, FRMM, BHST, and BTMD

How does Werewolf Therapeutics compare to Cue Biopharma?

Summary

How does Werewolf Therapeutics compare to eXoZymes?

Summary

How does Werewolf Therapeutics compare to Forum Markets?

Summary

How does Werewolf Therapeutics compare to BioHarvest Sciences?

Summary

How does Werewolf Therapeutics compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. CUE, EXOZ, FRMM, BHST, and BTMD

How does Werewolf Therapeutics compare to Cue Biopharma?

Do analysts recommend CUE or HOWL?

Is CUE or HOWL more profitable?

Do institutionals & insiders hold more shares of CUE or HOWL?

Which has preferable valuation and earnings, CUE or HOWL?

Which has more risk and volatility, CUE or HOWL?

Does the media favor CUE or HOWL?

Summary

How does Werewolf Therapeutics compare to eXoZymes?

Do institutionals and insiders have more ownership in HOWL or EXOZ?

Which has more risk and volatility, HOWL or EXOZ?

Does the media refer more to HOWL or EXOZ?

Do analysts rate HOWL or EXOZ?

Is HOWL or EXOZ more profitable?

Which has higher valuation & earnings, HOWL or EXOZ?

Summary

How does Werewolf Therapeutics compare to Forum Markets?

Do analysts rate FRMM or HOWL?

Does the media favor FRMM or HOWL?

Do insiders & institutionals hold more shares of FRMM or HOWL?

Which has higher earnings & valuation, FRMM or HOWL?

Which has more risk & volatility, FRMM or HOWL?

Is FRMM or HOWL more profitable?

Summary

How does Werewolf Therapeutics compare to BioHarvest Sciences?

Do analysts prefer BHST or HOWL?

Do insiders and institutionals believe in BHST or HOWL?

Which has more risk & volatility, BHST or HOWL?

Which has preferable valuation & earnings, BHST or HOWL?

Is BHST or HOWL more profitable?

Does the media prefer BHST or HOWL?

Summary

How does Werewolf Therapeutics compare to biote?

Which has preferable valuation & earnings, BTMD or HOWL?

Do insiders and institutionals believe in BTMD or HOWL?

Is BTMD or HOWL more profitable?

Do analysts prefer BTMD or HOWL?

Which has more risk & volatility, BTMD or HOWL?

Does the media prefer BTMD or HOWL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools